Journal of Shanghai Jiao Tong University (Medical Science) ›› 2024, Vol. 44 ›› Issue (3): 301-311.doi: 10.3969/j.issn.1674-8115.2024.03.002
• Basic research • Previous Articles
XU Wenhui(), YANG Chang, LI Ruiqing, BIAN Jing, LI Xiayi, ZHENG Leizhen(
)
Received:
2023-05-14
Accepted:
2024-03-19
Online:
2024-03-28
Published:
2024-04-29
Contact:
ZHENG Leizhen
E-mail:xuwenhui98@126.com;zhengleizhen@xinhuamed.com.cn
Supported by:
CLC Number:
XU Wenhui, YANG Chang, LI Ruiqing, BIAN Jing, LI Xiayi, ZHENG Leizhen. Exploratory study of interferon regulatory factor 3 promoting proliferation and invasion related to colorectal cancer cells[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(3): 301-311.
Fig 1 Kaplan-Meier survival analysis based on different IRF3 expression levelsNote: A. Renal cancer. B. Colorectal cancer. C. Liver cancer. D. Prostate cancer.
Fig 2 Comparison of immunohistochemical staining for IRF3 protein between cancerous and normal tissues adjacent to cancer in patients with colorectal cancer (×20)Note: A. Normal intestinal tissue adjacent to cancer. B. Cancerous tissue.
Fig 3 Comparison of immunohistochemical staining for IRF3 protein between cancerous and normal tissues adjacent to cancer from patients with renal cancer (×20)Note: A. Normal kidney tissue adjacent to cancer. B. Cancerous tissue.
1 | SUNG H, FERLAY J, SIEGEL R L, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. |
2 | 周雄, 胡明, 李子帅, 等. 2020年全球及中国结直肠癌流行状况分析[J]. 海军军医大学学报, 2022, 43(12): 1356-1364. |
ZHOU X, HU M, LI Z S, et al. Colorectal cancer in the world and China in 2020: an analysis of epidemic status[J]. Academic Journal of Naval Medical University, 2022, 43(12): 1356-1364. | |
3 | 李建, 张尧, 胡登敏, 等. 1990—2019年中国人群早发性结直肠癌疾病负担及变化趋势分析[J]. 现代预防医学, 2022, 49(19): 3468-3473. |
LI J, ZHANG Y, HU D M, et al. Disease burden and its time trends of early-onset colorectal cancer in China, 1990—2019[J]. Modern Preventive Medicine, 2022, 49(19): 3468-3473. | |
4 | ZHOU W K, WANG J M, WANG X, et al. Degradation of HDAC10 by autophagy promotes IRF3-mediated antiviral innate immune responses[J]. Sci Signal, 2022, 15(765): eabo4356. |
5 | ZHANG Q, LIU S D, ZHANG C S, et al. AMPK directly phosphorylates TBK1 to integrate glucose sensing into innate immunity[J]. Mol Cell, 2022, 82(23): 4519-4536.e7. |
6 | SUN X C, XIN S Y, LI W Y, et al. Discovery of Notch pathway-related genes for predicting prognosis and tumor microenvironment status in bladder cancer[J]. Front Genet, 2022, 13: 928778. |
7 | SONG J, ZHAO W, ZHANG X, et al. Mutant RIG-Ⅰ enhances cancer-related inflammation through activation of circRIG-Ⅰ signaling[J]. Nat Commun, 2022, 13: 7096. |
8 | SHAN S H, NIU J P, YIN R P, et al. Peroxidase from foxtail millet bran exerts anti-colorectal cancer activity via targeting cell-surface GRP78 to inactivate STAT3 pathway[J]. Acta Pharm Sin B, 2022, 12(3): 1254-1270. |
9 | SAIKRUANG W, ANG YAN PING L, ABE H, et al. The RNA helicase DDX3 promotes IFNB transcription via enhancing IRF-3/p300 holocomplex binding to the IFNB promoter[J]. Sci Rep, 2022, 12(1): 3967. |
10 | OKAMURA K, NAGAYAMA S, TATE T, et al. Lymphocytes in tumor-draining lymph nodes co-cultured with autologous tumor cells for adoptive cell therapy[J]. J Transl Med, 2022, 20(1): 241. |
11 | PASCOLUTTI R, YETURU L, PHILIPPIN G, et al. ATP128 clinical therapeutic cancer vaccine activates NF-κB and IRF3 pathways through TLR4 and TLR2 in human monocytes and dendritic cells[J]. Cancers, 2022, 14(20): 5134. |
12 | LIU J, JI Q L, CHENG F, et al. The lncRNAs involved in regulating the RIG-Ⅰ signaling pathway[J]. Front Cell Infect Microbiol, 2022, 12: 1041682. |
13 | YANG Y Y, CAO X Y, HUANG L S, et al. RNF19a inhibits antiviral immune response to RNA viruses through degradation of TBK1[J]. Mol Immunol, 2022, 143: 1-6. |
14 | 寻鲁宁, 王冲, 沈成凤, 等. 1990—2019年中国结直肠癌发病趋势分析及预测模型比较[J]. 中国肿瘤, 2023, 32(4): 279-286. |
XUN L N, WANG C, SHEN C F, et al. Prediction of colorectal cancer incidence in China with three different models based on trends from 1990 to 2019[J]. China Cancer, 2023, 32(4): 279-286. | |
15 | FANG X L, XU J F, JIN K T, et al. Combining of immunotherapeutic approaches with chemotherapy for treatment of gastric cancer: achievements and limitations[J]. Int Immunopharmacol, 2023, 118: 110062. |
16 | FANG G D, XU D L, ZHANG T, et al. Biological functions, mechanisms, and clinical significance of circular RNA in colorectal cancer[J]. Front Oncol, 2023, 13: 1138481. |
17 | UHLÉN M, BJÖRLING E, AGATON C, et al. A human protein atlas for normal and cancer tissues based on antibody proteomics[J]. Mol Cell Proteomics, 2005, 4(12): 1920-1932. |
18 | TIEDT R, KING F J, STAMM C, et al. Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors[J]. Cell Rep, 2023, 42(4): 112297. |
19 | WANG H Q, CUI B M, YAN H Y, et al. Targeting 7-dehydrocholesterol reductase against EV-A71 replication by upregulating interferon response[J]. Antivir Res, 2023, 209: 105497. |
20 | RUAN J Y, ZHANG P, ZHANG Q Q, et al. Colorectal cancer inhibitory properties of polysaccharides and their molecular mechanisms: a review[J]. Int J Biol Macromol, 2023, 238: 124165. |
21 | YAN X L, ZHENG W W, GENG S, et al. Cytokine receptor-like factor 3 negatively regulates antiviral immunity by promoting the degradation of TBK1 in teleost fish[J]. J Virol, 2023, 97(1): e0179222. |
22 | YANG S, JIN S H, XIAN H F, et al. Metabolic enzyme UAP1 mediates IRF3 pyrophosphorylation to facilitate innate immune response[J]. Mol Cell, 2023, 83(2): 298-313.e8. |
23 | JING T, ZHAO B Y, XU P B, et al. The structural basis of IRF-3 activation upon phosphorylation[J]. J Immunol, 2020, 205(7): 1886-1896. |
24 | KUHL N, LINDER A, PHILIPP N, et al. STING agonism turns human T cells into interferon-producing cells but impedes their functionality[J]. EMBO Rep, 2023, 24(3): e55536. |
25 | YUM S, LI M H, FANG Y, et al. TBK1 recruitment to STING activates both IRF3 and NF-κB that mediate immune defense against tumors and viral infections[J]. Proc Natl Acad Sci USA, 2021, 118(14): e2100225118. |
26 | GAO Q Z, ZHOU R, MENG Y, et al. Long noncoding RNA CMPK2 promotes colorectal cancer progression by activating the FUBP3-c-Myc axis[J]. Oncogene, 2020, 39(19): 3926-3938. |
27 | YANG L Q, HU H Y, HAN Y, et al. CpG-binding protein CFP1 promotes ovarian cancer cell proliferation by regulating BST2 transcription[J]. Cancer Gene Ther, 2022, 29(12): 1895-1907. |
28 | YANG J Q, ZHANG Q, WANG J L, et al. Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combination strategy of immunotherapy[J]. EBioMedicine, 2022, 78: 103958. |
29 | XU S S, LIU Y C, MA H S, et al. A novel signature integrated of immunoglobulin, glycosylation and anti-viral genes to predict prognosis for breast cancer[J]. Front Genet, 2022, 13: 834731. |
30 | YANG C S, JIVIDEN K, KAMATA T, et al. Androgen signaling uses a writer and a reader of ADP-ribosylation to regulate protein complex assembly[J]. Nat Commun, 2021, 12(1): 2705. |
31 | WANG L D, SUN X D, HE J N, et al. Functions and molecular mechanisms of deltex family ubiquitin E3 ligases in development and disease[J]. Front Cell Dev Biol, 2021, 9: 706997. |
32 | BOLIS M, PARONI G, FRATELLI M, et al. All-trans retinoic acid stimulates viral mimicry, interferon responses and antigen presentation in breast-cancer cells[J]. Cancers, 2020, 12(5): 1169. |
33 | AHMED S F, BUETOW L, GABRIELSEN M, et al. DELTEX2 C-terminal domain recognizes and recruits ADP-ribosylated proteins for ubiquitination[J]. Sci Adv, 2020, 6(34): eabc0629. |
34 | LO P K, YAO Y, LEE J S, et al. LIPG signaling promotes tumor initiation and metastasis of human basal-like triple-negative breast cancer[J]. eLife, 2018, 7: e31334. |
35 | ZHOU Y J, LI G L, WANG J Y, et al. PD-L1: expression regulation[J]. Blood Sci, 2023, 5(2): 77-91. |
36 | ROTMAN J, DEN OTTER L A S, BLEEKER M C G, et al. PD-L1 and PD-L2 expression in cervical cancer: regulation and biomarker potential[J]. Front Immunol, 2020, 11: 596825. |
37 | WU Y L, CHEN W Y, XU Z P, et al. PD-L1 distribution and perspective for cancer immunotherapy-blockade, knockdown, or inhibition[J]. Front Immunol, 2019, 10: 2022. |
38 | SHEN X, ZHAO B. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis[J]. BMJ, 2018, 362: k3529. |
39 | WANG X, TENG F F, KONG L, et al. PD-L1 expression in human cancers and its association with clinical outcomes[J]. Onco Targets Ther, 2016, 9: 5023-5039. |
[1] | DING Yanling, LI Jie, YUAN Jun, LI Yan. Research progress in targeted therapies of chronic lymphocytic leukemia [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(2): 264-270. |
[2] | ZHOU Wanzhen, TENG Yincheng. Research progress of the role of non-canonical Wnt signaling pathway in ovarian cancer and its potential therapeutic implications [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(8): 1056-1063. |
[3] | MEI Yanqing, HAN Yujie, WENG Wenyun, ZHANG Lei, TANG Yujie. In vitro therapeutic effects and molecular mechanisms of targeted inhibition of CDK12/13 in high-grade gliomas [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(5): 545-559. |
[4] | XU Yinglian, TIAN Jing, ZHANG Xiang, ZHAO Shunying. Research progress in the roles of airway epithelial cells in the pathogenesis of asthma [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(5): 619-623. |
[5] | WEI Lanyi, XUE Xiaochuan, CHEN Junjun, YANG Quanjun, WANG Mengyue, HAN Yonglong. Research progress of tumor-associated macrophages in immune microenvironment and targeted therapy of osteosarcoma [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(5): 624-630. |
[6] | LIU Tiexin, LIN Junqing, ZHENG Xianyou. Research progress of subcellular structure-targeted therapy in spinal cord injury [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(2): 230-236. |
[7] | QIN Yahan, ZHANG Ke, ZHANG Mengyu, SHEN Jie, PENG Meiyu. Research progress of MDSCs-targeted immunotherapy for pancreatic cancer [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(10): 1317-1323. |
[8] | HAN Yongqi, HAN Da, XIA Qian, JI Dingkun, TAN Weihong. Aptamer-drug conjugates (ApDCs): new trend for cancer precision therapy [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(9): 1176-1181. |
[9] | LI Ruonan, CHEN Xiaoke, XU Yuanyuan, TAN Qiang. Advances in postoperative adjuvant targeted therapy for patients with stage ⅠB-ⅢA non-small cell lung cancer [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(11): 1612-1619. |
[10] | Jia-ling ZHANG, Feng-chun ZHANG, Ying-chun XU. Research progress in the systemic treatment for breast cancer with brain metastasis [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(5): 671-677. |
[11] | LI Chao, MI Jian-qing, WANG Jin. Advances in Philadelphia chromosome-like acute lymphoblastic leukemia [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(9): 1294-1301. |
[12] | ZHANG Lin-yuan, ZHANG Ming, DA Jun. Application of mTOR inhibitor everolimus for the treatment of renal cell carcinoma [J]. , 2016, 36(12): 1812-. |
[13] | CHENG Kang, SUN Fu-kang. Role of PI3K/AKT/mTOR signaling pathway in development and progress of pheochromocytoma and its combined targeted therapies [J]. , 2015, 35(1): 137-. |
[14] | MIAO Ying, ZHANG Ling-fei, LIANG Sheng, et al. Experimental study on targeting and inhibiting hexokinase 2 by miR-143 for treatment of breast cancer [J]. , 2014, 34(8): 1107-. |
[15] | XU Fa-liang, ZHOU Qi, KUANG Yi, et al. Screening of DNA aptamers for recognizing tumor cells by using cell-systematic evolution of ligands by exponential enrichment [J]. , 2013, 33(12): 1684-. |
Viewed | ||||||||||||||||||||||||||||||||||||||||||||||||||
Full text 2336
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Abstract 368
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||